Jaguar Health (NASDAQ:JAGX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Monday, Zacks.com reports.
Separately, ValuEngine raised Jaguar Health from a “hold” rating to a “buy” rating in a research note on Friday, April 5th.
Shares of NASDAQ JAGX opened at $0.28 on Monday. Jaguar Health has a 52 week low of $0.12 and a 52 week high of $3.20.
About Jaguar Health
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Recommended Story: What is the Rule of 72?
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.